Clinical efifcacy and immunomodulatory effect ofpaclitaxel plus cisplatin in treatment of patient with advanced ovarian cancer
- VernacularTitle:紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效及其对免疫调节作用的研究
- Author:
Jinzhong SHU
;
Shisheng TAN
- Publication Type:Journal Article
- Keywords:
paclitaxel;
advanced ovarian cancer;
immunoregulation;
chemotherapy
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):120-122
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigatethe the clinical efifcacy and immunomodulatory effect of paclitaxel and cisplatin in treatment of advanced ovarian carcinoma by different administration ways. Methods 94 patients with advanced ovarian carcinoma were randomly divided into observation group and control group. Patients in observation group (47 cases) were treats with paclitaxel plus cisplation by intraperitoneal infusion chemotherapy, the other patients (47 cases) who are in control group were treats with paclitaxel plus cisplation by intravenous chemotherapy. Two groups used the same medicinal dose, and 3 weeks as a course. After two courses, therapeutic effect and drug toxicity side effects were evaluated by measuring positive rate changes of peripheral blood immune cells (CD 4+CD 25+cell), the CD 4+/CD 8+ratio changes, progression-free survival and 3-year survival rate. Results The efifcacy of patients in two groups were evaluated objectively. Observation group of RR and DC were respectively 78.7%and 91.5%, signiifcantly higher than that of control group. To the end of follow-up period, two groups of progression-free surial compared with a signiifcant difference. After two courses of chemotherapy, positive rate of immune cells (CD 4+CD 25+cell) declined had signiifcant difference compared with before treatment. After two courses of chemotherapy, two groups of CD 4+/CD 8+ratio were increased, compared with before treatment, which is a signiifcant difference. The main adverse reactions of the two groups were myelosuppression and neurotoxicity, but there were no termination of tolerance for adverse reactions. Conclusion The programs with paclitaxel plus cisplatin peritoneal perfusion chemotherapy for advanced ovarian cancer which is effective, small toxic and safe, is worthy of clinical application.
